According to the research report titled ‘Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market - Analysis By Drug Type, Distribution Channel, By Region, and By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)’, available with MarketStudyReport, global gastroesophageal reflux disease (GERD) therapeutics market was worth USD 5.5 billion in 2020 and is anticipated to garner notable returns by the year 2026.

Growing cognizance of the disease and its symptoms is the primary growth stimulant for worldwide gastroesophageal reflux disease (GERD) therapeutics market.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4121730/  

Moreover, rising prevalence of heartburn is expected to open new business opportunities for proton pump inhibitors and acid-reducing drugs, resulting in a rapid expansion of the industry.

For the unversed, gastroesophageal reflux illness is linked to rising obesity rate and adoption of other unhealthy diet, including shift toward sedentary habits, shorter dinner-to-bed time, high dietary fat intake, and frequent smoking & alcohol consumption.

Increasing risk of GERD disease in developing countries, as well as technical developments that allow for faster diagnosis are expected to boost the global gastroesophageal reflux disease (GERD) therapeutics industry size during the forecast timeframe.

Speaking of distribution channel, the market is branched into online pharmacies, retail pharmacies, and hospital pharmacies.

In terms of drug type, the industry is divided into protein pump inhibitors, H2 receptor blockers, and antacids. Among these, protein pump inhibitors (PPIs) segment has gained traction in the recent past, owing to PPIs being the front-line therapy treatment, and escalating demand from the U.S. and European countries.

Regionally speaking, North America market holds a significant revenue share and is anticipated to grow enormously during the review period. The expansion is attributed to surging incidences of obesity-related GERD, pharmacological innovation in GERD therapies, high per capita healthcare spending, combined with the longer life expectancy in the region.

The leading players in global gastroesophageal reflux disease therapeutics marketplace are Olympus Corporation, Merck & Co., Inc., Cheplapharm Arzneimittel GmbH, EndoGastric Solutions, Inc., Johnson & Johnson, Ironwood Pharmaceuticals, Inc., Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., and Phathom Pharmaceuticals, Inc.